Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Express Pharma
Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial
The TRANSCEND-T2D-2 trial found greater reductions in A1C, body weight and certain cardiovascular risk factors with retatrutide at 80 weeks The post Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial appeared first on Express Pharma.
Read Full Article
Express Pharma
Spektus Pharma, GEBRO partner to commercialise ActraFlex globally
The partnership covers Europe, the Americas and selected Rest of World markets for the twice-daily extended-release tramadol and paracetamol formulation The post Spektus Pharma, GEBRO partner to commercialise ActraFlex globally appeared first on Express Pharma.
Read Full Article
Express Pharma
DoP conducts 14,700 cleanliness drives under SCDPM 6.0
The Department of Pharmaceuticals has reviewed 4,283 physical files and 20 e-files, weeded out 489 files and freed 2,200 square feet of office space during the campaign The post DoP conducts 14,700 cleanliness drives under SCDPM 6.0 appeared first on Express Pharma.
Read Full Article
Express Pharma
NPPA revises MRPs of 543 brands of anti-cancer medicines
Revised prices will come into effect from November 9, 2026, following trade margin rationalisation of 137 non-scheduled anti-cancer drugs The post NPPA revises MRPs of 543 brands of anti-cancer medicines appeared first on Express Pharma.
Read Full Article
Pharma Tech
Ferring bets on Gameto’s reproductive health solution through $1.38bn takeoverÂ
Gameto’s lead asset is a cell-based IVM tool, Fertilo, which is currently in late-stage development within the US.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
PharmaShots
Oct 29, 2026, 8:43 AM
Junshi Biosciences Reports Final P-III (NEOTORCH) Trial Data of Toripalimab + Chemotherapy for Resectable Stage II-III NSCLC at ESMO 2026
Shots: Junshi Biosciences presented final analysis data from the P-III (NEOTORCH) trial of perioperative toripalimab (240mg, Q3W) + CT vs PBO + CT in pts (n=501) with resectable stage II-III NSCLC at ESMO 2026 (LBA64), published simultaneously in Annals of Oncology At a median follow-up of 48.2mos., EFS improved (HR=0.52; mEFS: NR vs 20.2mos.), with… The post Junshi Biosciences Reports Final P-III (NEOTORCH) Trial Data of Toripalimab + Chemotherapy for Resectable Stage II-III NSCLC at ESMO 2026 appeared first on PharmaShots.
Express Pharma
Oct 29, 2026, 8:17 AM
Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial
The TRANSCEND-T2D-2 trial found greater reductions in A1C, body weight and certain cardiovascular risk factors with retatrutide at 80 weeks The post Lilly’s retatrutide shows greater A1C reduction and weight loss than Ozempic in Phase 3 trial appeared first on Express Pharma.
Express Pharma
Oct 29, 2026, 7:30 AM
Spektus Pharma, GEBRO partner to commercialise ActraFlex globally
The partnership covers Europe, the Americas and selected Rest of World markets for the twice-daily extended-release tramadol and paracetamol formulation The post Spektus Pharma, GEBRO partner to commercialise ActraFlex globally appeared first on Express Pharma.
PharmaShots
Oct 29, 2026, 7:08 AM
Geron Discontinues P-III (IMpactMF) Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
Shots: Geron has discontinued the P-III (IMpactMF) trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis, based on the independent DMC’s recommendation that the trial was unlikely to meet its 1EP of OS The open-label trial randomized (2:1) 327 pts with intermediate-2 or high-risk MF to imetelstat (9.4mg/kg, IV, Q3W) or best available therapy; no new… The post Geron Discontinues P-III (IMpactMF) Trial of Imetelstat in Relapsed/Refractory Myelofibrosis appeared first on PharmaShots.
ET Pharma
Oct 29, 2026, 7:03 AM
Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini Piramal
The company is positioning its global manufacturing footprint as a way to offer customers greater flexibility, including nearshoring, offshore production and integrated manufacturing solutions.
PharmaShots
Oct 29, 2026, 7:02 AM
The US FDA Accepts Palvella Therapeutics’ NDA with Priority Review for QTORIN Rapamycin to Treat Microcystic Lymphatic Malformations
Shots: The US FDA has accepted & granted Priority Review to Palvella Therapeutics’ NDA for QTORIN 3.9% rapamycin anhydrous gel to treat microcystic lymphatic malformations (microcystic LMs), with a PDUFA date of Feb 28, 2027 The NDA is supported by the P-III (SELVA) trial, which met all 6 prespecified efficacy endpoints (all p<0.001), with 95%… The post The US FDA Accepts Palvella Therapeutics’ NDA with Priority Review for QTORIN Rapamycin to Treat Microcystic Lymphatic Malformations appeared first on PharmaShots.
News
Latest industry coverage
Google News
Oct 29, 2026, 9:05 AM
Democratic win could trigger scrutiny of Trump’s drug deals with Novo - medwatch.com
Democratic win could trigger scrutiny of Trump’s drug deals with Novo  medwatch.com
Google News
Oct 29, 2026, 9:00 AM
PSCI: Sustainably Transforming Pharma's Global Supply Chains - Supply Chain Digital Magazine
PSCI: Sustainably Transforming Pharma's Global Supply Chains  Supply Chain Digital Magazine
Google News
Oct 29, 2026, 9:00 AM
PSCI Lucy Latham on Sustainable Pharma Supply Chains - Supply Chain Digital Magazine
PSCI Lucy Latham on Sustainable Pharma Supply Chains  Supply Chain Digital Magazine
Google News
Oct 29, 2026, 9:00 AM
PSCI Chair Lucy Latham on Sustainable Pharma Supply Chains - Supply Chain Digital Magazine
PSCI Chair Lucy Latham on Sustainable Pharma Supply Chains  Supply Chain Digital Magazine
Google News
Oct 29, 2026, 9:00 AM
Canadians could save billions in next decade if off-patent drugs get to market quickly, report says - The Globe and Mail
Canadians could save billions in next decade if off-patent drugs get to market quickly, report says  The Globe and Mail
Google News
Oct 29, 2026, 8:30 AM
Biopharma industry at odds over impact of Treasury’s new China rule - STAT
Biopharma industry at odds over impact of Treasury’s new China rule  STAT
Google News
Oct 29, 2026, 8:11 AM
India pharma and healthcare deals hit record 87 in Q3 CY2026 as hospitals attract $1.8 billion in PE investments: Grant Thronton - Fortune India
India pharma and healthcare deals hit record 87 in Q3 CY2026 as hospitals attract $1.8 billion in PE investments: Grant Thronton  Fortune India
Google News
Oct 29, 2026, 8:00 AM
Global oncology innovation from Hengrui Pharma - pharmaphorum
Global oncology innovation from Hengrui Pharma  pharmaphorum
Google News
Oct 29, 2026, 7:55 AM
Labor in fresh budget fight as Greens back biotech sector - AFR
Labor in fresh budget fight as Greens back biotech sector  AFR
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer